oh no i mixed up the numbers in what i was trying to say.

i meant to say that a 700mg subQ dose is the same as a 350 mg intravenous dose.

so if cd16/cd17 gives first dose 700mg IV, that is the same as a 1400mg dose subcutaneous.

Except that the 2x only applies to time points greater than 48 hours after dosing, so the intravenous dose advantage is much greater still.

So a 700mg intravenous dose could be the equivalent of a 2800mg subcutaneous dose.

It might seem, "Well isnt there a safety problem here?"

No because the PRO140 trials gave people intravenous 700mg doses, which might be the equivalent of subcutaneous 2800mg doses, and the PRO140 trials had no safety issues at 700mg intravenous although it was only 10 or so patients.

Has there ever been a dose limiting toxicity of leronlimab in anything? I don't know. Maybe the limit is really high.

Some critical patients recover so quickly that the leronlimab almost seems to be performing some sort of switch function.

Maybe the reason the other patients do not recover quickly is because the toggle level on the bioswitch is not getting hit.

Maybe the intravenous dose will toggle the switch on a bunch more patients, I don't know.